Physician profile
Alyssa Coogan
NPI 1801302765
$6,529.24
in general payments reported to CMS, 2019-2025
25 companies · $2,523 in 2025
The $2,523 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $652 · 2023: $1,042 · 2024: $2,058 · 2025: $2,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,366 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,365.93 |
| Education | $256.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,054.01 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $912.88 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $776.99 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $663.26 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Genzyme Corporation | $490.89 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $443.56 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $310.86 | 2021-2025 | |
| Incyte Corporation | $285.96 | 2021-2025 | Opzelura |
| Amgen INC. | $275.06 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $273.19 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $250.95 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $231.67 | 2021-2025 | Nemluvio, Aklief, Dysport |
| Pfizer INC. | $95.85 | 2022-2025 | |
| Almirall LLC | $94.29 | 2022 | |
| Organon LLC | $65.70 | 2025 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $63.66 | 2024 | Daxxify |
| Fresenius Kabi USA, LLC | $59.93 | 2023-2025 | Idacio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.44 | 2024-2025 | Jublia, Cabtreo, Siliq |
| Dermavant Sciences, INC. | $31.69 | 2024 | Vtama |
| Lnhc, INC | $20.24 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2024 | Spevigo |
| Merck Sharp & Dohme LLC | $19.54 | 2024 | Keytruda |
| Sun Pharmaceutical Industries INC. | $19.41 | 2023 | Ilumya |
| Arcutis Biotherapeutics, INC. | $17.94 | 2024 | Zoryve |
| Botanix Sb INC | $17.70 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Coogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.